,
14 min read
Introduction: Why Most PMS Systems Look Strong but Fail Under Pressure
Across the medical device industry, post-market surveillance systems often appear robust. Organisations maintain complaint handling workflows, generate periodic reports, conduct clinical follow-ups, and meet regulatory submission timelines. From a compliance standpoint, everything seems to be in place.
Yet, when serious safety issues emerge in the field, a different reality surfaces. Investigations frequently reveal that early warning signs already existed, hidden within complaint data, scattered across service records, or buried in clinical feedback. The issue was not the absence of data, but the failure to interpret it in time.
This is the fundamental challenge of post-market surveillance. It is not a problem of process but of insight.
Regulators have increasingly recognised this gap. The European Commission, through its medical device regulatory framework, has moved toward lifecycle-based oversight, where manufacturers must continuously reassess safety and performance. Similarly, the FDA’s post-market requirements for devices emphasise ongoing monitoring and action rather than static compliance.
In this environment, post-market surveillance for medical devices is no longer about maintaining documentation. It is about building a system that can interpret weak signals, challenge assumptions, and act before risk becomes visible at scale, ensuring continuous monitoring of safety and performance throughout the product lifecycle.
What Post-Market Surveillance Actually Means in Practice
Post-market surveillance is often defined in regulatory language as the process of collecting and analysing data after a device is placed on the market. While accurate, this definition is incomplete. It frames PMS as an activity rather than what it truly is, a decision-making system under uncertainty.
In real-world settings, devices behave in ways that cannot always be predicted during pre-market evaluation. Clinical trials operate under controlled conditions, but once a device is introduced into routine clinical practice, variability increases significantly. Different patient populations, diverse usage environments, and human factors all introduce complexity that cannot be fully modelled in advance.
As a result, PMS must do more than gather information. It must interpret it in a way that connects individual data points to broader patterns as part of a structured post market surveillance process in medical devices, where data is continuously evaluated rather than simply recorded. A complaint, for instance, is rarely meaningful on its own. Its significance emerges only when it is contextualised alongside similar events, usage conditions, and clinical outcomes.
This is why regulators emphasise integration. The MDCG guidance documents explicitly position PMS as a lifecycle activity that feeds into clinical evaluation and risk management. Similarly, the FDA’s 522 Post-market Surveillance Studies Program reflects an expectation that post-market data should resolve uncertainty, not simply document it.
When PMS works effectively, it operates as a continuous loop in which data leads to insight, and insight leads to action.
The Scope of Post-Market Surveillance: What Data Actually Matters
One of the most common misconceptions about post-market surveillance is that it is primarily driven by complaints and adverse events. While these are important inputs, they represent only a portion of the data required to understand real-world device performance.
A comprehensive PMS system draws from a much broader range of data sources. These include not only internal data such as complaints, service reports, and manufacturing deviations, but also external sources such as published literature, clinical registries and user feedback. In practice, this often involves integrating real world evidence (RWE) alongside insights from clinical evaluation reports (CER) to build a more complete and reliable understanding of device performance in real-world settings.
The challenge is not just collecting this data but determining its relevance and reliability. Not all data carries equal weight, and organisations must establish criteria for evaluating what constitutes meaningful evidence. For example, isolated user feedback may provide early signals but requires validation, while clinical registry data may offer stronger evidence but with delayed availability.
Another critical aspect is data consistency and traceability. Without standardised methods for capturing and categorising data, it becomes difficult to compare trends over time or across geographies. This often leads to fragmented insights, where patterns exist but remain undetected due to a lack of structure.
Public data sources such as EUDAMED and the FDA MAUDE database further support transparency and enable broader signal detection across the industry.
Ultimately, the effectiveness of PMS depends on how well organisations define the scope of surveillance, not just in terms of regulatory requirements, but also on what data are necessary to truly understand device performance in real-world use.
Why Traditional PMS Approaches Break Down
Despite regulatory clarity, many organisations struggle to operationalise PMS effectively. The issue is rarely a lack of effort or intent. Instead, it stems from how PMS is structured and perceived internally.
One of the most common challenges is treating PMS as a reporting function rather than an intelligence function. Teams focus on generating outputs, such as complaint files, vigilance reports, and PSURs, but not on extracting forward-looking insights from the underlying data. The result is a system that is compliant but not predictive.
Another issue is fragmentation. Data on device performance often resides across multiple systems, including complaint databases, clinical records, service logs, and regulatory submissions. Without integration, these datasets remain isolated, making it difficult to identify patterns that span across them.
There is also a tendency to treat risk management as a static activity. Risk files are updated periodically, but not always in response to real-world signals. This creates a disconnect between documented risk and the device's actual performance.
Perhaps most critically, many organisations operate reactively. Action is taken only after issues become visible and significant. By that point, opportunities for early intervention have already been missed. These are common post market surveillance challenges across organisations.
These challenges highlight a fundamental shift that PMS must undergo, from passive monitoring to active interpretation.
How Effective PMS Systems Operate Differently
Organisations that excel in PMS do not necessarily have more data or more processes. What differentiates them is how they use what they already have.
Instead of focusing on whether data has been collected, they focus on what that data is revealing. Complaints are analysed not as isolated cases but as part of a broader pattern. Clinical data is used to challenge assumptions rather than confirm them. Reports are treated as outputs of insight, not as endpoints.
This shift changes how systems, such as product complaints management in medical devices, are positioned. Rather than serving as intake mechanisms, they become early-warning systems that feed into trend analysis and risk evaluation.
In this model, PMS shifts from compliance to situational awareness.
In more advanced PMS systems, this shift toward interpretation is supported by structured governance. Decision-making is not left to isolated teams; it is guided by cross-functional review mechanisms that bring together quality, regulatory, clinical, and risk management functions. These forums allow organisations to assess signals collectively, ensuring that different perspectives are considered before drawing conclusions. This not only improves the quality of decisions but also strengthens their defensibility during regulatory review.
Core Components of an Effective PMS System
An effective PMS system is not defined by the presence of individual components, but by how those components interact. Complaint handling, clinical follow-up, reporting, and risk management must function as parts of a connected system, where information flows continuously, and decisions are informed by evolving evidence.
1. Medical Device Complaints Handling: Interpreting Signals, Not Closing Cases
Complaint handling is often the first place where real-world issues surface. It provides direct insight into how devices behave outside controlled environments, capturing user experiences, unexpected failures, and edge cases.
However, the value of medical device complaint handling is frequently underestimated because it is treated as an operational task. A well-structured medical device complaint handling system ensures that complaints are not only recorded and closed, but analysed collectively to identify patterns, detect early signals, and support proactive decision-making. This also includes structured adverse event reporting in medical devices, ensuring that safety-related incidents are communicated to regulatory authorities in a timely and compliant manner.
A more mature approach views complaints as part of a larger dataset. It asks not only whether a complaint is reportable, but whether it contributes to a pattern. When multiple complaints share similar characteristics, they may point to underlying issues that require further investigation.
This shift transforms complaint handling into a strategic function, where the focus moves from case management to insight generation.
Another important dimension is the quality of investigation. Superficial root-cause analysis often limits the value of complaint data, leading to recurring issues that are never fully understood. Effective PMS systems invest in deeper investigation methodologies that link complaints to design inputs, manufacturing processes, and user interaction patterns. This allows organisations to move beyond symptom identification and address underlying causes, improving both product performance and long-term risk management.
2. Recalls, Corrections, and Removals: The Outcome of Surveillance Quality
Recalls are often perceived as failures, but they are more accurately understood as indicators of how well a PMS system functions. While some actions are immediate responses to acute failures, many field safety corrective actions (FSCAs) result from accumulated evidence reaching a threshold for intervention.
In many cases, risks escalate into such actions when early signals are not identified in time. This highlights the importance of timely interpretation and response.
Processes related to medical device recall, corrections and removals should therefore be viewed as extensions of PMS rather than separate operational activities. They represent the point at which insight is translated into action.
3. PMS Planning and Reporting: Moving Beyond Template Compliance
PMS documentation plays a central role in demonstrating compliance, but its value extends beyond regulatory requirements. Beyond satisfying authorities, well-structured PMS plans and reports serve as internal reference points that guide decision-making across teams. When these documents clearly define responsibilities, escalation pathways, and evaluation criteria, they reduce ambiguity and enable more consistent responses to emerging issues.
Both the post market surveillance plan and the post market surveillance report must reflect real-world insights rather than template-based documentation.
The challenge, however, is that PMS documentation often becomes standardised templates that do not reflect actual practice. A PMS Plan may outline data sources and methodologies, but not how decisions are made. Similarly, reports may summarise data without explaining their implications. A more effective approach treats these documents as decision frameworks that explain how data are connected, how trends are evaluated, and how conclusions are reached.
This is where post-market surveillance plans and reports become critical, providing structure while supporting meaningful interpretation.
Under EU MDR, reporting requirements vary by device class. While Periodic Safety Update Reports (PSUR) apply to Class IIa and above, Class I devices require a Post-Market Surveillance Report (PMSR), reflecting a proportionate approach to lifecycle monitoring.
4. PMCF: Addressing What Is Still Unknown
Post-Market Clinical Follow-Up (PMCF) is often misunderstood as an additional regulatory burden. It is one of the most strategic elements of PMS because it focuses on reducing uncertainty.
As part of post market clinical follow up (PMCF) activities, organisations are expected to continuously generate clinical evidence that supports long-term safety and performance in real-world use.
Another challenge in PMCF is balancing scientific rigour with operational feasibility. While comprehensive clinical studies can provide valuable insights, they are often resource-intensive and time-consuming. Organisations must adopt a pragmatic approach, combining evidence-generating methods such as real-world data, retrospective analyses, and targeted follow-up studies.
The effectiveness of PMCF depends on how well these uncertainties are identified. Generic data-collection efforts rarely yield meaningful insights. Instead, PMCF should be targeted and designed to address specific knowledge gaps.
Guidance such as the MDCG 2020-7 (PMCF Plan guidance) reinforces this approach, emphasising the need for structured and purposeful clinical follow-up.
5. PSUR: Where Insight Becomes Visible
The periodic safety update report (PSUR) in medical devices serves as a comprehensive summary of safety, performance, and benefit-risk evaluation based on accumulated post-market data. It brings together data from multiple sources and presents a coherent view of a device’s benefit-risk profile, enabling continuous evaluation of safety and performance based on real-world data.
A well-developed PSUR does more than summarise data. It explains trends, justifies conclusions, and demonstrates how decisions are made. Regulators use PSUR not only to assess safety, but to evaluate how well an organisation understands its own data.
This expectation is reflected in the MDCG 2022-21 (PSUR guidance), which emphasises consistency and structured evaluation.
6. Signal Detection: The Shift Toward Predictive Surveillance
The future of PMS lies in signal detection, the ability to identify patterns before they become significant issues. This requires moving beyond reactive reporting and adopting analytical approaches that can detect subtle changes in data.
This process operates within a broader vigilance system in medical devices, where data from multiple sources is continuously monitored to identify emerging risks and trends.
Importantly, signal detection is not solely dependent on advanced technology. While analytics tools can enhance visibility, interpreting signals still relies on a human-in-the-loop (HITL) approach, where automated signal detection is complemented by expert review to ensure that decisions are clinically and regulatorily justified. Understanding whether a trend represents a true safety concern or a benign variation requires clinical, regulatory, and engineering judgment. This human element remains essential, particularly in high-risk scenarios where decisions must be made with incomplete or evolving data.
Programs such as the FDA’s 522 Post-market Surveillance Studies Program highlight the growing importance of using post-market data to answer critical safety questions.
Regulatory Reality: Beyond FDA vs EU MDR
The industry often frames PMS complexity as a difference between regulatory systems. However, the real challenge lies in execution. Both the FDA and EU MDR expect continuous monitoring, risk-based evaluation, and data-driven decision-making.
These requirements are defined under EU MDR Regulation (EU) 2017/745 and further supported by MDCG guidance documents, which emphasise lifecycle-based surveillance and continuous evaluation. They are further formalised under EU MDR Articles 83–86, requiring manufacturers to establish a systematic and proactive post-market surveillance system.
In addition, ISO 20416 provides international guidance on establishing effective post-market surveillance systems aligned with global best practices.
Organisations that struggle with PMS do so not because of regulatory differences, but because their systems are not designed to integrate data and support interpretation.
Common Challenges in PMS Implementation
Even well-established organisations encounter recurring challenges in PMS implementation. These challenges often stem from structural issues rather than a lack of effort. Surveillance activities may be treated as periodic rather than continuous, leading to delayed recognition of trends. Data may remain fragmented across systems, limiting visibility into cross-functional insights.
In some cases, organisations overemphasise documentation while underutilising analytical capabilities, resulting in reports that summarise data rather than interpret it. Perhaps most critically, action is often delayed until signals become obvious, reducing the opportunity for early intervention.
Addressing these challenges requires rethinking how PMS is positioned within the organisation.
The Future of Post-Market Surveillance
PMS is moving toward a more predictive and data-driven model. Advances in analytics, artificial intelligence, and real-world evidence are enabling earlier risk detection and more informed decision-making.
At the same time, regulatory expectations are evolving alongside these technological advancements. Authorities are increasingly focusing on how organisations use data rather than simply whether it is collected. This means that the ability to explain decision-making, justify conclusions, and demonstrate continuous evaluation will become as important as the data itself. In this context, PMS will increasingly serve as both a compliance function and a strategic capability that differentiates organisations in terms of safety, reliability, and trust.
The real shift, however, is not technological; it is conceptual. The organisations that will lead are not those with the most data, but those that can interpret ambiguity faster and act on incomplete information with regulatory confidence.
The future of PMS is not just about faster detection, but about explainable intelligence where insights are not only generated but clearly understood, justified, and defensible in regulatory contexts
Conclusion: From Compliance Systems to Intelligence Systems
Post-market surveillance is often described as a regulatory requirement, but in practice, it is far more consequential: a reflection of how well an organisation understands its product once it enters the real world.
The distinction between compliant and effective PMS systems lies in their ability to interpret uncertainty. While many organisations successfully collect data and meet reporting obligations, fewer can translate that data into early insight. This is where surveillance shifts from being a process to becoming an intelligence system.
As regulatory expectations continue to evolve under EU MDR and FDA frameworks, the emphasis is no longer on whether PMS activities are performed, but on whether they are meaningful. Regulators increasingly expect manufacturers to demonstrate not just documentation, but also the reasoning behind how conclusions are reached, how risks are identified, and how decisions are justified.
Looking ahead, the future of PMS will be defined by integration and interpretation. Organisations that connect data across complaints, clinical evidence, and risk management, and use it to make timely, defensible decisions, will be better positioned to manage uncertainty, maintain compliance, and improve patient outcomes.
In this sense, PMS is no longer the end of the product lifecycle. It is the mechanism through which the lifecycle is continuously understood, challenged, and improved.
Ultimately, effective post-market surveillance ensures that the benefit-risk profile of medical devices remains favourable throughout their lifecycle, supported by continuous monitoring and evidence-based decision-making.
How Freyr Can Help
For many organisations, the challenge in post-market surveillance is not the absence of processes, but the lack of alignment between them. Complaint handling, clinical evaluation, risk management, and regulatory reporting often operate in silos, making it difficult to develop a unified, timely understanding of device performance.
Freyr approaches post-market surveillance as an integrated system rather than a set of independent activities. By connecting data across the product lifecycle and enabling consistent interpretation of signals, Freyr helps organisations strengthen the translation of surveillance into decision-making. This includes aligning complaint trends with risk updates, linking clinical insights to ongoing evaluations, and ensuring that regulatory outputs reflect a clear, defensible narrative.
The focus is not on adding complexity, but on improving clarity, helping organisations move from reactive reporting to continuous, evidence-based surveillance that is scalable and aligned with evolving global expectations.
If you are evaluating your current PMS approach or looking to strengthen how surveillance translates into decision-making. Connect with Freyr’s experts to further explore your post-market surveillance strategy and requirements.
Frequently Asked Questions (FAQs)
The primary objective of post-market surveillance is to continuously evaluate whether a medical device maintains a favourable benefit-risk profile in real-world clinical use. It enables manufacturers to identify emerging risks, validate clinical performance, and ensure that regulatory compliance reflects actual device behaviour throughout the product lifecycle.
Post-market surveillance supports risk management by providing real-world evidence that can confirm, refine, or challenge initial risk assumptions. It ensures that risk assessments are continuously updated based on actual device performance, enabling manufacturers to respond to evolving safety concerns in a timely, evidence-based manner.
PMCF is critical not only for addressing residual uncertainties but also as a proactive requirement under EU MDR to continuously generate clinical evidence throughout the device lifecycle. Even in the absence of identified gaps, PMCF ensures that safety and performance are consistently validated in real-world use.
Signal detection improves PMS effectiveness by identifying patterns and trends in data before they escalate into significant safety issues. By analysing data across complaints, clinical evidence, and other sources, organisations can detect weak signals early and take proactive action, thereby reducing the likelihood of larger regulatory or patient-safety risks.
